Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2785–2808 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Myofascial Pain, Chronic Pain, Extremities Disorders, Osteopathic Manipulation
Interventions: Fascial Distortion Model (FDM), Standard Care; Procedure · Other
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Christiansburg, Virginia • Lexington, Virginia • Roanoke, Virginia + 1 more

Conditions: Schizophrenia
Interventions: PF-06412562 3mg BID, PF-06412562 9mg BID, PF-06412562 45mg BID, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Arcadia, California • Glendale, California • Baltimore, Maryland + 2 more

Conditions: Safety
Interventions: SBT115301, Placebo; Biological
Lead sponsor: Sonoma Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Spinal Cord Injury
Interventions: FES-row-training, Arms-only-row training, Time Control; Other
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 20 Years to 40 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Breakfast, Appetitive Behavior
Interventions: Breakfast; Dietary Supplement
Lead sponsor: Purdue University; Other
Eligibility: 15 Years to 21 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Cervical Dystonia
Interventions: incobotulinumtoxinA (Xeomin) (240 Units), incobotulinumtoxinA (Xeomin) (120 Units), Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes, Control Condition
Interventions: 12 week progressive exercise training; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Heart Defects, Congenital, Hypertension, Pulmonary
Interventions: L-citrulline, Placebo of intravenous L-citrulline; Drug
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: Up to 17 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Inflammatory Bowel Diseases
Interventions: Infliximab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Colorectal Neoplasms
Interventions: GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab; Drug
Lead sponsor: Seattle Project Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 43
States / cities: Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more

Conditions: CTLA4 Haploinsufficency, Chronic Cytopenia
Interventions: abatacept, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: PN2034, Insulin; Drug
Lead sponsor: Wellstat Therapeutics; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 18
States / cities: Waterbury, Connecticut • Hollywood, Florida • Longwood, Florida + 14 more

Conditions: Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component, Recurrent Glioblastoma, Relapsed Glioblastoma
Interventions: Bevacizumab, Rindopepimut (CDX-110) with GM-CSF, KLH; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more

Conditions: Marker; Structural
Interventions: Specimen #1, Specimen #2; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 5 Years to 50 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Schizo-affective Disorder, Bipolar Disorder
Interventions: Glycine, placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Atrial Fibrillation, Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Deliberate Self Harm
Interventions: N-Acetylcysteine, fMRI; Dietary Supplement · Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 13 Years to 21 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Metabolic Syndrome X
Interventions: NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo; Drug · Device · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions: Sirolimus in combination with ranibizumab, Placebo in combination with ranibizumab; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: HIV
Interventions: atazanavir/raltegravir, atazanavir/tenofovir/emtricitabine; Drug
Lead sponsor: Community Research Initiative of New England; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more

Conditions: Colorectal Neoplasms
Interventions: Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2032
U.S. locations: 989
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more

Conditions: Diabetes Mellitus Type 1
Interventions: ORMD-0801 Capsules, Placebo; Biological · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Tustin, California

Conditions: Herpes Labialis
Interventions: onabotulinumtoxinA, Bacteriostatic normal saline; Drug · Other
Lead sponsor: DeNova Research; Other
Eligibility: 18 Years to 64 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Neuralgia, Spinal Cord Injuries
Interventions: placebo, pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 22
States / cities: Phoenix, Arizona • Fresno, California • Napa, California + 15 more

Search by objective public record fields.

FDM for Subacute and Chronic Extremity Pain in the ED

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Study of Single Doses of SBT115301 in Healthy Participants

Hybrid-FES Exercise to Prevent Cardiovascular Declines in Acute SCI

High Protein Breakfast on Weight Management and Glycemic Control in 'Breakfast-skipping' Teens

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia

Exercise and Protein Efficiency in T2D

Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery

Safety of Reduced Infliximab Infusion Time

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

Effects of PN2034 in Insulin-Dependent Patients With Type 2 Diabetes

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Fatty Acid Binding Proteins and Markers of Cellular Senescence in Cancer Survivors

Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents

Mechanisms of Cerebrovascular Control

Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

S0820, Adenoma and Second Primary Prevention Trial

A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics

Botulinum Toxin A for Herpes Labialis

A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury